Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Disulfiram-Loaded Niosomes Reduces Cancerous Phenotypes in Oral Squamous Cell Carcinoma Cells Publisher



Motlagh MZ1, 2 ; Mahdavi N1, 3 ; Mirilavasani Z2 ; Aminishakib P1, 3 ; Khoramipour M2 ; Arki MK2 ; Rezaei N2 ; Hosseinkhannazer N2 ; Vosough M4, 5
Authors

Source: Cell Journal Published:2023


Abstract

Objective: Surgery and chemotherapy are the most common therapeutic strategies proposed for oral squamous cell carcinoma (OSCC). However, some of the disadvantages associated with the current methods like unwanted side effects and poor drug response lead the scientist to seek for novel modalities and delivery approaches to enhance the efficacy of treatments. The study aimed to assess the effectiveness of disulfiram (DSF)-loaded Niosomes on cancerous phenotypes of the OSCC cells. Materials and Methods: In this experimental study, an optimum formulation of DSF-loaded Niosomes was developed for the treatment of OSCC cells to reduce drug doses and improve the poor stability of DSF in the OSCC environment. The design expert software was utilized to optimize the particles in terms of size, polydispersity index (PDI), and entrapment effcacy (EE). Results: Acidic pH increased the release rate of DSF from these formulations. The size, PDI, and EE of Niosomes were more stable at 4°C compared to 25°C. The results indicated that DSF-loaded Niosomes could induce apoptosis (P=0.019) in the OSCC cells compared to the control group. Moreover, it could reduce colony formation ability (P=0.0046) and also migration capacity of OSCC cells (P=0.0015). Conclusion: Our findings indicated that the application of proper dose of DSF-loaded Niosomes (12.5 µg/ml) increases apoptosis, decreases colony formation capacity and declines the migration ability of OSCC cells. © 2023 Royan Institute (ACECR). All rights reserved.
Other Related Docs
4. Niosomal Delivery of Simvastatin to Mda-Mb-231 Cancer Cells, Drug Development and Industrial Pharmacy (2020)
7. Niosomal Formulation for Antibacterial Applications, Journal of Drug Targeting (2022)